Pleiotropic functions of FOXC2 in EMT, stem cells and breast cancer progression
Pleiotropic functions of FOXC2 in EMT, stem cells and breast cancer progression
批准号:
9524466
负责人:
Sendurai Ayyavoo Mani
金额:
$32.87万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-03-16 至 2023-07-31
关键词:
AnaphaseBindingBreast Cancer PatientCancer ControlCancer PatientCell CycleCell Differentiation processCell NucleusCell divisionCellsCessation of lifeCharacteristicsChemotherapy-Oncologic ProcedureChromatinClinicalCompetenceComplement Factor BDataDaughterDevelopmental ProcessDiseaseElementsEpithelialEquilibriumFOXC2 geneGenerationsGenetically Engineered MouseIn VitroInflammatoryInterphaseLaboratoriesLinkMaintenanceMammary NeoplasmsMediatingMesenchymalMetaphaseMetastatic breast cancerMitoticModelingMolecularMonitorMusNeoplasm MetastasisNumbnessOutcomePLK1 genePathway interactionsPatientsPhosphotransferasesPhysiologicalProcessPropertyProphaseProtein IsoformsRNA BindingRNA SplicingRecurrenceRelapseReporterResistanceResistance developmentRiskRoleSeminalSignal PathwaySignal TransductionStem cellsSystemTestingTransforming Growth FactorsXenograft procedurebreast cancer progressionburden of illnesscancer cellcancer cell differentiationcancer stem cellcell typecytokinedaughter celldesignexhaustexhaustionin vivoinhibitor/antagonistinnovationmalignant breast neoplasmnotch proteinnovelnovel strategiespreventprogramsself-renewalsmall molecule inhibitorstem cell differentiationstem cell divisionstem cell populationtelophasetherapeutic targettherapy resistanttraittranscription factortumortumor microenvironmenttumor progressionubiquitin ligase
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Development of resistance to therapies, tumor relapse, and metastasis pose significant risks to breast cancer
patients and are responsible for the majority deaths among these cancer patients. Recent studies have
demonstrated that the developmental process is known as epithelial-mesenchymal-transition (EMT) as well as
a subpopulation of cancer cells termed cancer stem cells (CSC), in these various processes. We and others
have shown that the EMT program and stem cell properties are interconnected, and specifically, cancer cells
are capable of acquiring stem cell attributes through the activation of EMT. This suggested that targeting EMT
program may reduce the disease burden and will decrease death among cancer patients. However, the dearth
of signaling pathways emanating from the tumor microenvironment capable of inducing EMT - including
inflammatory cytokines and transforming growth factor β-1 (TGFβ1) makes it impossible to therapeutically target
EMT. Cumulative studies from our laboratory over the last 9 years have resulted in the seminal identification of
the transcription factor FOXC2, as a key player in metastasis and also as a common downstream effector of
multiple EMT-signaling pathways and indispensable for the procurement of CSC properties. A characteristic
feature of CSCs is their capability to self-renew via asymmetrical or symmetrical self-renewal type of cell divisions
thereby enabling the continued existence and expansion of the CSC pool. The current proposal will
systematically test the role of FOXC2 as a critical element of the molecular switch facilitating CSC self-renewal
and expansion, and investigate if aberrant activation of FOXC2 leads to increase in CSC populations via Notch
signaling, resulting in tumor progression and metastasis. We will use a combination of in vitro-, and in vivo tumor
models, and patient-derived xenografts as well as genetically engineered mouse models to tease out this
process. We will also examine the function of TGFβ1, a physiologically relevant inducer of EMT, in dictating
FOXC2-induced CSC expansion. Also, we will evaluate FOXC2-regulated mitotic bookmarking in maintaining
the identity of the CSCs following stem cell division. Finally, we will test select small molecule inhibitors capable
of modulating FOXC2-function in selectively preventing CSC expansion during EMT. Significance: In summary,
our proposal will not only help clarify the fundamental processes regulating CSC self-renewal and expansion of
CSCs during EMT but will also contribute to designing novel strategies that would provide an opportunity to shift
the balance of CSC towards more differentiated cells and exhaust therapy-resistant, metastasis-prone CSCs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Vimentin Phospho-Malleability is Critical for Maintaining Stemness and Metastatic Properties
-
批准号:10795597
-
项目类别:
-
资助金额:$39.72万
-
财政年份:2023
-
负责人:Sendurai Ayyavoo Mani
-
依托单位:
Pleiotropic functions of FOXC2 in EMT, stem cells and breast cancer progression
-
批准号:10764124
-
项目类别:
-
资助金额:$32.11万
-
财政年份:2011
-
负责人:Sendurai Ayyavoo Mani
-
依托单位:
Pleiotropic functions of FOXC2 in EMT, stem cells and breast cancer progression
-
批准号:10477993
-
项目类别:
-
资助金额:$0.1万
-
财政年份:2011
-
负责人:Sendurai Ayyavoo Mani
-
依托单位:
Pleiotropic functions of FOXC2 in EMT, stem cells and breast cancer progression
-
批准号:8243511
-
项目类别:
-
资助金额:$33.37万
-
财政年份:2011
-
负责人:Sendurai Ayyavoo Mani
-
依托单位:
Pleiotropic functions of FOXC2 in EMT, stem cells and breast cancer progression
-
批准号:8616354
-
项目类别:
-
资助金额:$31.76万
-
财政年份:2011
-
负责人:Sendurai Ayyavoo Mani
-
依托单位:
Pleiotropic functions of FOXC2 in EMT, stem cells and breast cancer progression
-
批准号:8444687
-
项目类别:
-
资助金额:$30.97万
-
财政年份:2011
-
负责人:Sendurai Ayyavoo Mani
-
依托单位:
Pleiotropic functions of FOXC2 in EMT, stem cells and breast cancer progression
-
批准号:10228015
-
项目类别:
-
资助金额:$32.87万
-
财政年份:2011
-
负责人:Sendurai Ayyavoo Mani
-
依托单位:
Pleiotropic functions of FOXC2 in EMT, stem cells and breast cancer progression
-
批准号:8026259
-
项目类别:
-
资助金额:$33.37万
-
财政年份:2011
-
负责人:Sendurai Ayyavoo Mani
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: